Robert Abouassaly, MD, MS

Robert Abouassaly, MD, MS

Cleveland Clinic

Cleveland, Ohio

Robert Abouassaly, MD, MS, is the Institute Chief of the Integrated Surgical Institute at the Cleveland Clinic in Cleveland, Ohio. Dr. Abouassaly specializes in nephrectomy, prostate biopsy, and laparoscopic and robotic procedures.

Dr. Abouassaly earned his medical degree from McGill University in Montreal, Canada. He completed an internship in Surgery and a residency in Urology at the Cleveland Clinic. Dr. Abouassaly completed a fellowship in Urologic Oncology at the University of Toronto in Canada. 

Dr. Abouassaly served as a Staff Urologist at Cleveland Clinic’s main campus in Ohio, where he was also Director of Urology for the Western Region and Director of Urology at Fairview Hospital. He has held clinical appointments at University Hospitals Case Medical Center and the Louis Stokes Cleveland Veterans Association Medical Center. In addition, he has held several leadership positions, including Continuous Improvement Officer and Chair of the Prostate Excision Surgery Center of Excellence Committee.

Talks by Robert Abouassaly, MD, MS

An Overview of MRI Guided Biopsies for Prostate Cancer

An Overview of MRI Guided Biopsies for Prostate Cancer

| Feb 2018

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.” 

Read More
Can the DECIPHER Marker Predict Chemotherapy?

Can the DECIPHER Marker Predict Chemotherapy?

| Jan 2018

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.” 

Read More